Dendrite Collaborates with Microsoft to Create Next Generation Solutions for Life Sciences

  
    
  
  
    
      Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of 
      pharmaceutical industry solutions, today announced a strategic 
      relationship with Microsoft Corp. (NASDAQ: MSFT) aimed at developing new 
      Dendrite solutions on the Microsoft software platform.
    
    
      Dendrite’s pharmaceutical expertise – 
      coupled with Microsoft’s technologies in 
      business intelligence (BI) and performance management – 
      will produce solutions to enable pharmaceutical companies to reach 
      prescribers and patients more effectively. Dendrite will develop its 
      solutions on a range of Microsoft products, including Microsoft SQL 
      Server 2005, Windows Vista and Windows Mobile.
    
    
      As part of this relationship, Dendrite will also participate in Microsoft’s 
      Technology Adoption Program (TAP) which seeks to obtain real-world 
      customer feedback on Microsoft pre-release products. In turn, Microsoft 
      will work closely with Dendrite’s R&D efforts 
      to enable faster development cycles of life science-specific solutions 
      that give companies a competitive advantage.
    
    
      “As the global pharmaceutical industry 
      continues to rapidly evolve, it creates a unique set of circumstances 
      that require companies to respond quickly, reliably and efficiently,” 
      said Subhash Vaid, Dendrite vice president of product marketing. “We’re 
      optimistic that Dendrite’s vast 
      pharmaceutical industry experience and Microsoft’s 
      strength in technology will lead to the creation of a whole new set of 
      rich solutions that will cater to these needs.”
    
    
      “Pharmaceutical companies are faced with the 
      need to communicate directly to consumers as well as physicians in new 
      ways, while adding savings to the bottom line,” 
      said Paul Mattes, industry solutions director, U.S. Pharmaceutical and 
      Life Sciences Vertical Group, Microsoft. ”This 
      expanded relationship will allow companies to benefit from Dendrite’s 
      pharmaceutical expertise, while leveraging their existing IT investments 
      with Microsoft’s familiar and easy-to-use 
      technology.”
    
    
      Dendrite’s strategic decision in July to make 
      its flagship sales force effectiveness solution Mobile IntelligenceTM 
      available on Microsoft SQL Server 2005 was a first step in the 
      relationship aimed at providing life science customers with additional 
      options that could result in a lower total cost of ownership. As a 
      result of this collaboration, the first application is expected to be 
      available during the first quarter of 2007 in the United States and 
      Japan.
    
    
      About Dendrite
    
    
      Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, 
      marketing, clinical and compliance solutions for the global 
      pharmaceutical industry. The Company’s 
      clients are located in more than 50 countries and include the world's 
      top 20 pharmaceutical companies.
    
    
      Note: Dendrite is a registered trademark of Dendrite International, Inc.
    
    
      This document may contain forward-looking statements that may be 
      identified by such forward-looking terminology as "expect," "believe," 
      "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," 
      and similar statements or variations. Such forward-looking statements 
      are based on our current expectations, estimates, assumptions and 
      projections and involve significant risks and uncertainties, including 
      risks which may result from our dependence on the pharmaceutical 
      industry; fluctuations in quarterly revenues due to lengthy sales and 
      implementation cycles for certain of our solutions; our fixed expenses 
      in relation to fluctuating revenues and variations in customers' budget 
      cycles; dependence on certain major customers; changes in demand for our 
      products and services attributable to any weakness experienced in the 
      economy or mergers, acquisitions and consolidations in the 
      pharmaceutical industry; successful and timely development and 
      introduction of new products and versions; rapid technological changes; 
      increased competition; international operations; integrating the 
      entities we acquire; our ability to effectively manage our growth; the 
      protection of our proprietary technology; our ability to compete in the 
      Internet-related products and services market; the continued demand for 
      Internet-related products and services; the ability of our third party 
      vendors to respond to technological change; our ability to maintain our 
      relationships with third-party vendors; less favorable than anticipated 
      results from strategic relationships; dependence of data solutions on 
      strategic relationships; events which may affect the U.S. and world 
      economies; and catastrophic events which could negatively affect our 
      information technology infrastructure. Other important factors that 
      should be reviewed and carefully considered are included in the 
      company's 10-K, 10-Qs, and other reports filed with the SEC. Actual 
      results may differ materially. The company assumes no obligation for 
      updating any such forward-looking statements to reflect actual results, 
      changes in assumptions or other changes affecting such forward-looking 
      statements.
    
  
Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of
pharmaceutical industry solutions, today announced a strategic
relationship with Microsoft Corp. (NASDAQ: MSFT) aimed at developing
new Dendrite solutions on the Microsoft software platform.

   Dendrite's pharmaceutical expertise - coupled with Microsoft's
technologies in business intelligence (BI) and performance management
- will produce solutions to enable pharmaceutical companies to reach
prescribers and patients more effectively. Dendrite will develop its
solutions on a range of Microsoft products, including Microsoft SQL
Server 2005, Windows Vista and Windows Mobile.

   As part of this relationship, Dendrite will also participate in
Microsoft's Technology Adoption Program (TAP) which seeks to obtain
real-world customer feedback on Microsoft pre-release products. In
turn, Microsoft will work closely with Dendrite's R&D efforts to
enable faster development cycles of life science-specific solutions
that give companies a competitive advantage.

   "As the global pharmaceutical industry continues to rapidly
evolve, it creates a unique set of circumstances that require
companies to respond quickly, reliably and efficiently," said Subhash
Vaid, Dendrite vice president of product marketing. "We're optimistic
that Dendrite's vast pharmaceutical industry experience and
Microsoft's strength in technology will lead to the creation of a
whole new set of rich solutions that will cater to these needs."

   "Pharmaceutical companies are faced with the need to communicate
directly to consumers as well as physicians in new ways, while adding
savings to the bottom line," said Paul Mattes, industry solutions
director, U.S. Pharmaceutical and Life Sciences Vertical Group,
Microsoft. "This expanded relationship will allow companies to benefit
from Dendrite's pharmaceutical expertise, while leveraging their
existing IT investments with Microsoft's familiar and easy-to-use
technology."

   Dendrite's strategic decision in July to make its flagship sales
force effectiveness solution Mobile Intelligence(TM) available on
Microsoft SQL Server 2005 was a first step in the relationship aimed
at providing life science customers with additional options that could
result in a lower total cost of ownership. As a result of this
collaboration, the first application is expected to be available
during the first quarter of 2007 in the United States and Japan.

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies.

   Note: Dendrite is a registered trademark of Dendrite
International, Inc.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; fluctuations in quarterly revenues due to
lengthy sales and implementation cycles for certain of our solutions;
our fixed expenses in relation to fluctuating revenues and variations
in customers' budget cycles; dependence on certain major customers;
changes in demand for our products and services attributable to any
weakness experienced in the economy or mergers, acquisitions and
consolidations in the pharmaceutical industry; successful and timely
development and introduction of new products and versions; rapid
technological changes; increased competition; international
operations; integrating the entities we acquire; our ability to
effectively manage our growth; the protection of our proprietary
technology; our ability to compete in the Internet-related products
and services market; the continued demand for Internet-related
products and services; the ability of our third party vendors to
respond to technological change; our ability to maintain our
relationships with third-party vendors; less favorable than
anticipated results from strategic relationships; dependence of data
solutions on strategic relationships; events which may affect the U.S.
and world economies; and catastrophic events which could negatively
affect our information technology infrastructure. Other important
factors that should be reviewed and carefully considered are included
in the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to reflect
actual results, changes in assumptions or other changes affecting such
forward-looking statements.